NCT01306032

ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Study identifier: NCT01306032
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

Participants must be diagnosed with BRCA1/2 ovarian cancer, primary peritoneal or ovarian high-grade carcinoma, or fallopian tube cancer whose disease has progressed after at least one line of therapy.

Type of study:

Randomized, Phase II trial

Treatment:

Participants who have BRCA-positive ovarian cancer, primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer will be randomized to receive either the combination of ABT-888 and cyclophosphamide, or cyclophosphamide alone

Study sites:

For all study sites, please contact:

Deborah E. Allen, R.N. (301) 402-5640 allendeb@mail.nih.gov

California

University of California, Davis     
Davis, California, 95616

Florida

H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida,  33612

Illinois

University of Chicago     
Chicago, Illinois, 60637

Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pike   
Bethesda, Maryland, United States, 20892

Minnesota

Mayo Clinic, Rochester  
Rochester, Minnesota, 55905

Nebraska

University of Nebraska Med. Ctr. Eppley Cancer Ctr.
Omaha, Nebraska, 68198-5950

New York

Montefiore Medical Center
Bronx, New York, 10467

Memorial Sloan Kettering Cancer Center
New York, New York, 10021

Ohio

Ohio State University      
Columbus, Ohio, United States, 43210-1240

Texas

MD Anderson Cancer Center
Houston, Texas, 77030-4096

Ontario

Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9 

 

Page updated 03/27/11  

Web design by Rareheron Web Design